UBS Group
ANRO icon

UBS Group’s Alto Neuroscience ANRO Stock Holding History

UBS Group’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55M Buy
58,697
+41,447
+240% +$958K ﹤0.01% 5341
2026
Q1 		$388K Sell
17,250
-1,239
-7% -$23K ﹤0.01% 6252
2025
Q4 		$329K Sell
18,489
-120,542
-87% -$1.52M ﹤0.01% 6306
2025
Q3 		$559K Sell
139,031
-289,185
-68% -$959K ﹤0.01% 6011
2025
Q2 		$942K Sell
428,216
-81,994
-16% -$195K ﹤0.01% 5499
2025
Q1 		$1.1M Buy
510,210
+107,813
+27% +$386K ﹤0.01% 5203
2024
Q4 		$1.7M Buy
402,397
+367,389
+1,049% +$2.29M ﹤0.01% 4879
2024
Q3 		$400K Buy
35,008
+32,318
+1,201% +$396K ﹤0.01% 5383
2024
Q2 		$28.8K Buy
2,690
+1,823
+210% +$23.7K ﹤0.01% 7086
2024
Q1 		$13.3K Buy
+867
New +$13.6K ﹤0.01% 7109

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

UBS Group's ANRO Position: Q2 2026 in Review

UBS Group increased its Alto Neuroscience (ANRO) stake by 240% in Q2 2026, buying an estimated $958K and bringing the position to 58,697 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #5341.

UBS Group first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.7M in Q4 2024. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • UBS Group held 58,697 shares of Alto Neuroscience worth $1.55M as of Q2 2026.
  • UBS Group bought 41,447 Alto Neuroscience shares in Q2 2026, an estimated $958K.
  • Alto Neuroscience made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5341 holding.
  • UBS Group first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
  • UBS Group's Alto Neuroscience position peaked at $1.7M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.